Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Cohort
2.2. PET/CT Acquisition
2.3. Data Analysis
2.4. Statistical Analysis
3. Results
3.1. Initial PET/CT Findings
3.2. Follow-Up Examination
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
- Hofman, M.S.; Lawrentschuk, N.; Francis, R.J.; Tang, C.; Vela, I.; Thomas, P.; Rutherford, N.; Martin, J.M.; Frydenberg, M.; Shakher, R.; et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet 2020, 395, 1208–1216. [Google Scholar] [CrossRef] [PubMed]
- Perera, M.; Papa, N.; Christidis, D.; Wetherell, D.; Hofman, M.S.; Murphy, D.G.; Bolton, D.; Lawrentschuk, N. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. 2016, 70, 926–937. [Google Scholar] [CrossRef] [PubMed]
- Fendler, W.P.; Calais, J.; Eiber, M.; Flavell, R.R.; Mishoe, A.; Feng, F.Y.; Nguyen, H.G.; Reiter, R.E.; Rettig, M.B.; Okamoto, S.; et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019, 5, 856–863. [Google Scholar] [CrossRef] [PubMed]
- Janssen, J.C.; Meissner, S.; Woythal, N.; Prasad, V.; Brenner, W.; Diederichs, G.; Hamm, B.; Makowski, M.R. Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. Eur. Radiol. 2018, 28, 610–619. [Google Scholar] [CrossRef]
- Evangelista, L.; Maurer, T.; van der Poel, H.; Alongi, F.; Kunikowska, J.; Laudicella, R.; Fanti, S.; Hofman, M.S. [(68)Ga]Ga-PSMA Versus [(18)F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur. Urol. Oncol. 2022, 5, 273–282. [Google Scholar] [CrossRef]
- Cardinale, J.; Roscher, M.; Schäfer, M.; Geerlings, M.; Benešová, M.; Bauder-Wüst, U.; Remde, Y.; Eder, M.; Nováková, Z.; Motlová, L.; et al. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors. J. Med. Chem. 2020, 63, 10897–10907. [Google Scholar] [CrossRef]
- Rahbar, K.; Afshar-Oromieh, A.; Seifert, R.; Wagner, S.; Schafers, M.; Bogemann, M.; Weckesser, M. Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 2055–2061. [Google Scholar] [CrossRef]
- Giesel, F.L.; Knorr, K.; Spohn, F.; Will, L.; Maurer, T.; Flechsig, P.; Neels, O.; Schiller, K.; Amaral, H.; Weber, W.A.; et al. Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J. Nucl. Med. 2019, 60, 362–368. [Google Scholar] [CrossRef]
- Kuten, J.; Fahoum, I.; Savin, Z.; Shamni, O.; Gitstein, G.; Hershkovitz, D.; Mabjeesh, N.J.; Yossepowitch, O.; Mishani, E.; Even-Sapir, E. Head-to-Head Comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J. Nucl. Med. 2020, 61, 527–532. [Google Scholar] [CrossRef]
- Schmuck, S.; Nordlohne, S.; von Klot, C.A.; Henkenberens, C.; Sohns, J.M.; Christiansen, H.; Wester, H.J.; Ross, T.L.; Bengel, F.M.; Derlin, T. Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 960–968. [Google Scholar] [CrossRef] [PubMed]
- Kunikowska, J.; Kujda, S.; Krolicki, L. 68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination? Clin. Nucl. Med. 2020, 45, e213–e214. [Google Scholar] [CrossRef]
- Hoffmann, M.A.; Buchholz, H.G.; Wieler, H.J.; Rosar, F.; Miederer, M.; Fischer, N.; Schreckenberger, M. Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. Cancers 2020, 12, 2788. [Google Scholar] [CrossRef] [PubMed]
- Hoberuck, S.; Lock, S.; Borkowetz, A.; Sommer, U.; Winzer, R.; Zophel, K.; Fedders, D.; Michler, E.; Kotzerke, J.; Kopka, K.; et al. Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: A retrospective single-center analysis. EJNMMI Res. 2021, 11, 109. [Google Scholar] [CrossRef] [PubMed]
- Grunig, H.; Maurer, A.; Thali, Y.; Kovacs, Z.; Strobel, K.; Burger, I.A.; Muller, J. Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: A multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4483–4494. [Google Scholar] [CrossRef] [PubMed]
- Lopez-Mora, D.A.; Flotats, A.; Fuentes-Ocampo, F.; Camacho, V.; Fernandez, A.; Ruiz, A.; Duch, J.; Sizova, M.; Domenech, A.; Estorch, M.; et al. Comparison of image quality and lesion detection between digital and analog PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1383–1390. [Google Scholar] [CrossRef]
- Nguyen, N.C.; Vercher-Conejero, J.L.; Sattar, A.; Miller, M.A.; Maniawski, P.J.; Jordan, D.W.; Muzic, R.F., Jr.; Su, K.H.; O’Donnell, J.K.; Faulhaber, P.F. Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET. J. Nucl. Med. 2015, 56, 1378–1385. [Google Scholar] [CrossRef]
- Alberts, I.; Prenosil, G.; Sachpekidis, C.; Weitzel, T.; Shi, K.; Rominger, A.; Afshar-Oromieh, A. Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: A matched-pair comparison. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 614–623. [Google Scholar] [CrossRef]
- Eiber, M.; Herrmann, K.; Calais, J.; Hadaschik, B.; Giesel, F.L.; Hartenbach, M.; Hope, T.; Reiter, R.; Maurer, T.; Weber, W.A.; et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J. Nucl. Med. 2018, 59, 469–478. [Google Scholar] [CrossRef]
- Seifert, R.; Telli, T.; Opitz, M.; Barbato, F.; Berliner, C.; Nader, M.; Umutlu, L.; Stuschke, M.; Hadaschik, B.; Herrmann, K.; et al. Unspecific (18)F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer. J. Nucl. Med. 2023, 64, 738–743. [Google Scholar] [CrossRef]
- Arnfield, E.G.; Thomas, P.A.; Roberts, M.J.; Pelecanos, A.M.; Ramsay, S.C.; Lin, C.Y.; Latter, M.J.; Garcia, P.L.; Pattison, D.A. Clinical insignificance of [(18)F]PSMA-1007 avid non-specific bone lesions: A retrospective evaluation. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4495–4507. [Google Scholar] [CrossRef] [PubMed]
- Hammes, J.; Hohberg, M.; Tager, P.; Wild, M.; Zlatopolskiy, B.; Krapf, P.; Neumaier, B.; Schomacker, K.; Kobe, C.; Schmidt, M.; et al. Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT. PLoS ONE 2018, 13, e0209613. [Google Scholar] [CrossRef] [PubMed]
- Kroenke, M.; Mirzoyan, L.; Horn, T.; Peeken, J.C.; Wurzer, A.; Wester, H.J.; Makowski, M.; Weber, W.A.; Eiber, M.; Rauscher, I. Matched-Pair Comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity. J. Nucl. Med. 2021, 62, 1082–1088. [Google Scholar] [CrossRef] [PubMed]
- Vollnberg, B.; Alberts, I.; Genitsch, V.; Rominger, A.; Afshar-Oromieh, A. Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 3910–3916. [Google Scholar] [CrossRef] [PubMed]
- Dietlein, F.; Kobe, C.; Hohberg, M.; Zlatopolskiy, B.D.; Krapf, P.; Endepols, H.; Tager, P.; Hammes, J.; Heidenreich, A.; Persigehl, T.; et al. Intraindividual Comparison of (18)F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. J. Nucl. Med. 2020, 61, 729–734. [Google Scholar] [CrossRef]
- Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3, 81–85. [Google Scholar]
- Froehner, M.; Toma, M.; Zophel, K.; Novotny, V.; Laniado, M.; Wirth, M.P. PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. Case Rep. Urol. 2017, 2017, 1654231. [Google Scholar] [CrossRef]
- Plouznikoff, N.; Garcia, C.; Artigas, C.; Entezari, K.; Flamen, P. Heterogeneity of 68Ga-PSMA PET/CT Uptake in Fibrous Dysplasia. Clin. Nucl. Med. 2019, 44, e593–e594. [Google Scholar] [CrossRef]
- Ninatti, G.; Pini, C.; Gelardi, F.; Ghezzo, S.; Mapelli, P.; Picchio, M.; Antunovic, L.; Briganti, A.; Montorsi, F.; Landoni, C.; et al. The potential role of osteoporosis in unspecific [(18)F]PSMA-1007 bone uptake. Eur. J. Nucl. Med. Mol. Imaging 2023, 51, 304–311. [Google Scholar] [CrossRef]
- Maisto, C.; Aurilio, M.; Morisco, A.; de Marino, R.; Buonanno Recchimuzzo, M.J.; Carideo, L.; D’Ambrosio, L.; Di Gennaro, F.; Esposito, A.; Gaballo, P.; et al. Analysis of Pros and Cons in Using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer. Molecules 2022, 27, 3862. [Google Scholar] [CrossRef]
- Luo, L.; Wang, Z.; Wang, X.; Gao, J.; Zheng, A.; Duan, X. Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: Clinical and PET/CT features to predict outcomes and prognosis. Clin. Radiol. 2024, 79, 346–353. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, I.S.; Kelly, M.D.; Williams, H.A.; Matthews, J.C. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. EJNMMI Phys. 2014, 1, 99. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.; Shen, Y. Study on the distribution features of bone metastases in prostate cancer. Nucl. Med. Commun. 2012, 33, 379–383. [Google Scholar] [CrossRef] [PubMed]
- Lamothe, F.; Kovi, J.; Heshmat, M.Y.; Green, E.J. Dissemination of prostatic carcinoma: An autopsy study. J. Natl. Med. Assoc. 1986, 78, 1083–1086. [Google Scholar]
- Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch, M.J. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 2000, 31, 578–583. [Google Scholar] [CrossRef]
- Rowe, S.P.; Pienta, K.J.; Pomper, M.G.; Gorin, M.A. Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. J. Nucl. Med. 2018, 59, 479–485. [Google Scholar] [CrossRef]
Group A (n = 56) | Group B (n = 24) | Group C (n = 19) | |
---|---|---|---|
Age [years] | 70 ± 6 | 66 ± 9 | 69 ± 7 |
Gleason score: 6–7 [n] 8–10 [n] | 35 21 | 11 13 | 10 9 |
Initial serum PSA [ng/mL] | 3.9 ± 8.2 | 1.6 ± 1.8 | 5.4 ± 6.6 |
Tracer dose [MBq] | 317 ± 17 | 314 ± 13 | 314 ± 12 |
Uptake time [min] | 72 ± 14 | 66 ± 12 | 71 ± 14 |
SUVmean blood pool | 2.1 ± 0.6 | 2.6 ± 0.5 | 2.2 ± 0.7 |
SUVmean spleen | 10.8 ± 3.9 | 8.9 ± 2.1 | 10.8 ± 4.9 |
SUVmean parotid gland | 17.4 ± 4.9 | 18.6 ± 4.7 | 20.3 ± 5.1 |
UBU [n] | 230 | 0 | 54 |
UBU SUVpeak | 2.7 ± 0.8 | - | 2.6 ± 0.5 |
Metastases [n] | - | - | 28 |
Metastases SUVpeak | - | - | 7.7 ± 8.1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Benecke, J.-A.; Calderón, E.; Reischl, G.; Brendlin, A.; Tsaur, I.; la Fougère, C.; Vogel, J. Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up. Diagnostics 2024, 14, 2327. https://doi.org/10.3390/diagnostics14202327
Benecke J-A, Calderón E, Reischl G, Brendlin A, Tsaur I, la Fougère C, Vogel J. Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up. Diagnostics. 2024; 14(20):2327. https://doi.org/10.3390/diagnostics14202327
Chicago/Turabian StyleBenecke, Jonas-Alexander, Eduardo Calderón, Gerald Reischl, Andreas Brendlin, Igor Tsaur, Christian la Fougère, and Jonas Vogel. 2024. "Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up" Diagnostics 14, no. 20: 2327. https://doi.org/10.3390/diagnostics14202327
APA StyleBenecke, J. -A., Calderón, E., Reischl, G., Brendlin, A., Tsaur, I., la Fougère, C., & Vogel, J. (2024). Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up. Diagnostics, 14(20), 2327. https://doi.org/10.3390/diagnostics14202327